Biopharmaceutical Company Achieves Major Milestone Towards Tropical Disease Treatment

In a significant development towards combating neglected tropical diseases, PaxMedica, Inc. (NASDAQ: PXMD), a pioneering biopharmaceutical company, has announced reaching a crucial milestone in the development of PAX-101, an intravenous formulation of suramin. This achievement marks a pivotal step in enabling a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for the potential treatment of Stage 1 Human African Trypanosomiasis (HAT), also known as sleeping sickness. The disease, caused by Trypanosoma brucei rhodesiense, is a fatal condition if left untreated and has remained a challenge in parts of Africa due to its neglect and lack of effective treatments available in the United States. $PaxMedica(PXMD.US)$